Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers
NCT ID: NCT00584675
Last Updated: 2015-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2007-02-28
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux
NCT01308502
Mechanisms Preventing Pharyngeal Reflux
NCT05696184
Evaluating Treatment Response in Laryngo-Pharyngeal Reflux
NCT01328392
A Validation Study of the Dx-pH Probe in Children for the Detection of Extra-oesophageal Reflux
NCT02457429
Diagnostic Tests in Supra-Esophageal Gastroesophageal Reflux Disease (SE-GERD)
NCT05695846
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dx-pH Measurement Probe
Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no symptoms of laryngopharyngeal reflux or gastroesophageal reflux disease
* score less than 10 on Reflux Symptom Index
Exclusion Criteria
* known lidocaine allergy
* history of heartburn, regurgitation, chronic cough, voice changes, globus pharyngeus, excessive throat clearing, or swallowing problems
* score 10 or greater on Reflux Symptom Index
* current or past antacid use or other antireflux therapy
* history of antireflux surgery
* pregnancy
* current anticoagulation therapy (warfarin, heparin, aspirin, clopidogrel bisulfate)
* special/vulnerable populations (children, mentally handicapped, pregnant women, fetuses, prisoners, cognitive impairment, life-threatening disease, social or economic disadvantage)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Davis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of California Davis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Belafsky, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Davis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Davis Medical Center
Sacramento, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200714988-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.